Rheumatoid arthritis (RA) is a chronic, systemic inflammatory disease that affects 0.5-1.0% of the general population. 1 As the disease progresses, the inflammatory process of the synovium of the joints destroys articular architecture irreversibly. In the late stage, the disease causes a significant disability and high medical costs. About half of RA patients are unable to work at some time in the disease. Lifetime costs for RA were reported to be comparable to those for coronary artery disease or stroke. 2 Moreover, life expectancy is shorter than the general population. Unfortunately, the cause of RA is still unknown. However, as the understanding of the pathophysiology of RA progresses, new therapeutic strategies and agents have been developed. The efficacy of early and aggressive treatment with disease-modifying antirheumatic drugs (DMARDs) is widely accepted. DMARDs, such as methotrexate (MTX), sulfasalazine (SSZ) and leflunomide, have documented prevention of the structural damage of the joints. 3, 4 Recently, biologic response modifiers targeting specific cytokines, such as tumor necrosis factor-a (TNF-a) or interleukin-1, have been introduced, and the results indicated the effective suppression of the RA activity. However, the outcome of the treatment with DMARDs in RA patients is known to vary among patients. The difference in the response has been reported in biologic response modifiers. 5, 6 Moreover, the use of these agents is limited by the development of unpredictable toxicities that are sometimes severe. Previously, it was described that the activities of some drug-metabolizing enzymes for DMARDs, such as Nacetyltransferase 2 (NAT2) for SSZ 7 and thiopurine methyltransferase (TPMT) for azathioprine (AZA), 8 are different among individuals. Recent advances in genetics have clarified that these individual differences are based on genetic polymorphisms, and this knowledge has encouraged the application of phamacogenetics to the treatment of RA.
MTX is one of the most widely used DMARDs for the treatment of RA. The principal pharmacological mechanism is thought to be the inhibition of dihydrofolate reductase, a key enzyme in the generation of bioactive folate compounds. Although precise mechanisms of action of MTX in RA remain controversial, it is widely accepted that the in vivo action of MTX is tightly related to the inhibition of the folate metabolism. [9] [10] [11] Several wellcontrolled trials revealed the efficacy of MTX in RA. Nevertheless, the response rate to MTX has been reported to be only 46 3 to 65%, 12 and the dose of MTX required to suppress effectively RA activity differs widely between patients. Toxicities of MTX can occur in some patients but not in others. 13 Thus, the variabilities in both efficacy and toxicity indeed exist in the treatment of RA with MTX. As MTX was suggested to exert its efficacy and at least part of its toxicity through the inhibition of folate metabolism, it is possible that genetic polymorphisms in enzymes involved in folate metabolism may be related to these differential effects. The enzyme 5,10-methylenetetrahydrofolate reductase (MTHFR) is central to folate metabolism. Among more than 10 polymorphisms of MTHFR gene, C677T and A1298C are important because these polymorphisms are associated with reduced enzyme activities. 14, 15 The reduction in the activities of this enzyme is likely to influence the development of efficacy or toxicity of MTX.
A prospective study involving 236 patients with RA in whom MTX was administered showed the association between the presence of T allele in the genotype at C677T polymorphism and the increased rate of the discontinuation of MTX treatment because of toxicities (relative risk (RR): 2.01; 95% confidence interval (CI): 1.09-3.70), mainly due to an increased risk of elevated liver enzyme levels (RR 2.38; 95% CI: 1.06-5.34). 16 Efficacy parameters were not significantly different between the patients with and without the mutation. The authors speculated that impeded homocysteine metabolism introduced by intracellular conversion of folate was the mechanism of the increased frequency of toxicities in patients with the mutant allele at C677T polymorphism. 16 In a retrospective study involving 106 patients with RA receiving MTX, the relationship between the two MTHFR gene polymorphisms, C677T and A1298C, and either the efficacy or the toxicity of MTX was examined. 17 Single-locus analysis showed that the patients with 1298C were receiving significantly lower doses of MTX compared to the patients without it (Po0.05; RR 2.18; 95% CI: 1.17-4.06), while a higher rate of overall MTX toxicity was observed in the patients with 677T than those without it (Po0.05; RR 1.25; 95% CI: 1.05-1.49). Haplotype analysis revealed that the patients with the 677C-1298C haplotype were receiving lower doses of MTX than those without it (Po0.05; RR 2.14; 95% CI: 1.13-4.07), while the subjects with 677T-1298A had a higher frequency of toxicities from MTX (Po0.05; RR 1.42; 95% CI: 1.11-1.92). 17 These studies suggested that C677T and A1298C polymorphisms within the MTHFR gene might be useful to predict the efficacy or the toxicity of MTX in the treatment of RA patients.
Recently, the anti-inflammatory effects of MTX medicated by adenosine metabolism have been reported to be an important mechanism. 18 However, enzymes in the adenosine pathways influenced by MTX have not been studied pharmacogenetically yet.
SSZ is another widely used DMARD. The frequency of the toxicities with SSZ has been reported to be about 20-30% in patients with RA. [19] [20] [21] NAT2 is a key enzyme in the acetylation of SSZ. The rate of acetylation is genetically determined and follows a bimodal distribution. Individuals were classified as fast and slow acetylators. 7 The NAT2 gene has several SNPs in exon 2 and it has been reported that slow acetylation is due to mutations in the NAT2 gene. 22 The haplotypes of single individuals were inferred based on the genotypes at seven SNP loci. The genetic status of each individual at the NAT2 gene is most properly expressed as a combination of two haplotypes, that is, a diplotype configuration. 22, 23 The NAT2 activity for an individual was related to the diplotype configuration. The presence of at least one wild-type haplotype (NAT2*4) in an individual resulted in a rapid acetylator phenotype, whereas homozygotes for mutant haplotypes (NAT2*5, NAT2*6, NAT2*7, NAT2*13, etc) resulted in a slow acetylator phenotype. [22] [23] [24] Tanaka et al 25 retrospectively examined whether the diplotype configurations at the NAT2 gene were associated with toxicities of SSZ in 144 Japanese RA patients. The frequency of the patients with toxicities was five of eight (62.5%) among the slow acetylators and only 11 of 136 (8.1%) among the rapid acetylators (Po0.001; odds ratio (OR): 7.73; 95% CI: 3.54-16.86). In 25% of the slow acetylators, toxicities, such as myelosuppression and hepatotoxicity, were so severe that hospitalization was required (Po0.005; OR: 17.0; 95% CI: 2.74-105.5). It was suggested that pretreatment genotyping of the NAT2 gene may reduce the incidence of toxicities, especially severe ones, of SSZ in RA patients. 21 AZA is widely used to treat certain malignancies, organ transplant rejections, inflammatory bowel diseases and rheumatic diseases including RA. However, a high discontinuation rate caused by toxicities has limited its use. Among three major enzymes involved in the metabolism of AZA, only TPMT has been extensively studied pharmacogenetically. TPMT activity is affected by allelic polymorphisms. Homozygotes for wild-type alleles (TPMT*1) had high TPMT activities, while homozygotes for mutant alleles such as TPMT*2 (G238C), TPMT*3A (G460A and A719G), TPMT*3B (G460A) and TPMT*3C (A719G) had low or no activities. Heterozygotes with both wild-type and mutant alleles had intermediate activities. 26, 27 TPMT-deficient patients accumulate very high concentrations of thioguanine nucleotides, the toxic metabolites of AZA, which leads to the severe bone marrow toxicity. There have been several reports on the association between the genotypes at TPMT and the toxicity of AZA in patients with rheumatic diseases. 28, 29 Black et al analyzed the TPMT genotype in a prospective cohort of 67 patients with rheumatic diseases that included 49 patients with RA. In the cohort, six of 67 patients were heterozygous and no patients were homozygous for mutant TPMT alleles. Five of the six heterozygous patients discontinued AZA within 1 month of therapy because of the reduced leukocyte counts. Patients with wild-type TPMT alleles had received treatment with AZA for significantly longer periods than patients with mutant alleles (P ¼ 0.018), although the data limited to patients with RA were not available. 28 Corominas et al investigated the association between TPMT genotype and toxicities of AZA in patients with RA in an observational study. In 40 patients with RA treated with AZA, three of five patients with mutant TPMT alleles discontinued AZA because of gastrointestinal toxicities with severe nausea and vomiting. Patients with mutant TPMT alleles had developed toxicities more frequently than those without mutant alleles (P ¼ 0.018). 29 These studies suggested the possibility that testing for TPMT genotypes before treatment with AZA would help clinical management of patients with rheumatic diseases. Economical analyses suggested that PCR screening for TPMT polymorphisms in patients with RA prior to AZA treatment appeared to be cost-effective. 30, 31 Although AZA is now used less frequently in the treatment of RA than before, the genotyping at TPMT before the treatment with AZA is a prototype of the individualized drug therapy for RA patients.
Recently, biologic response modifiers have been introduced for the treatment of RA. Since TNF-a plays a key role in the pathogenesis of RA, this cytokine might be one of the important targets of biologic response modifiers. Anti-TNF-a agents including etanercept, a recombinant soluble TNF receptor p75 fusion protein, and infliximab, a chimeric anti-TNF-a monoclonal antibody, are available in clinical practice. These agents proved to be effective for RA from various viewpoints including the radiographic progression. However, 20-40% of patients have been reported as nonresponders. 6 For biologic response modifiers targeting inflammatory cytokines, polymorphisms associated with the genes that regulate either the production or the function of the cytokines may influence the response to these agents. 6 Previous studies showed that A allele at À308GA polymorphism within the TNF-a gene (TNFA) promoter might be related to the high production of TNF-a. 32, 33 Mugnier et al 34 reported that A/A or A/G genotypes at À308 position of TNFA were associated with a poor response to infliximab therapy. The combination of G allele at À308 position in TNFA and the GG genotype at À1087 polymorphism in interleukin-10
Pharmacogenetic approaches to rheumatoid arthritis gene was reported to be associated with a good response to etanercept. 6 Although larger-scale studies including genotypes on various cytokines, cytokine receptors or antagonists will be needed, these studies suggested that the pharmacogenetic approach may be useful for predicting efficacy of anti-TNF-a treatment and for saving medical cost because these agents are extremely expensive.
The study on the phamacogenetic approach to the treatment of RA has just started. The above-mentioned studies suggest that the application of phamacogenetics may reduce toxicities and enhance the desirable effects of therapeutic agents. At present, pharmacogenetic studies are focused on small numbers of candidate genes for given antirheumatic drugs. The pharmacogenetic studies on MTX, SSZ and AZA suggested that it might be feasible to find genes that are associated with metabolic differences related to inexpensive antirheumatic drugs. However, such an approach might be insufficient because examinations have been concentrated mainly on genes that are expected to influence drug response. 35 More systematic and genome-wide studies might be effective to identify genes associated with relatively rare metabolic differences. Establishment of the SNP databases (http://www.ncbi.nlm.-nih.gov/SNP/, http://snp.ims.u-tokyo.ac.jp/index_ja.html) as well as the high-throughput low-cost genotyping systems has enabled us to perform such studies. In addition to the single SNP analysis, haplotype analysis may be useful. The latter method incorporates linked SNP data and examines the association between phenotypes and genotypes. Furthermore, accurate statistical methods are necessary to analyze large-scale data including clinical information and genetic polymorphisms. The clinical application of pharmacogenetics to the treatment of RA will be facilitated by the development of more effective technologies in such fields as genotyping, data analysis and effective clinical data storage as well as the accumulation of the results of the studies on the association between genetic polymorphisms and the individual differences in the responses to the drugs. 
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